Understanding how cannabidiol (CBD) exerts its myriad effects on human physiology is a work in progress. Thus far, scientists have identified more than 60 different molecular pathways through which CBD operates. It is known, for example, that CBD acts through multiple receptor-independent channels and it also binds to various receptors in the brain, including serotonin 5HT1A (which contributes to CBD’s antidepressant effect), TRPV1 (which contributes to CBD’s anti-psychotic effect), the nuclear receptor PPAR-gamma (regulates gene expression), and the orphan receptor GPR55, among others.
In a recent article, Eric Dolan, Editor of PsyPost reported on a ground-breaking pilot study on cannabis.
Scientists have begun examining tetrahydrocannabivarin, a little-known components of cannabis. Their preliminary findings suggest the chemical can inhibit some of the negative effects of cannabis’s main component.